ProCE Banner Activity

CE / CME

New and Emerging Drug Therapies for Generalized Pustular Psoriasis

Clinical Thought

There is no definitive guideline for the management of generalized pustular psoriasis (GPP) and treatment typically follows that of plaque psoriasis. New drugs inhibiting interleukin-36 have demonstrated robust efficacy, with spesolimab the only currently FDA-approved treatment for GPP.

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: October 05, 2023

Expiration: October 04, 2024

No longer available for credit.

Share

Faculty

Boni Elewski

Boni Elewski, MD

James Elder Professor
Department Chair
Department of Dermatology
Heersink School of Medicine
The University of Alabama at Birmingham
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This program is intended for primary care and dermatology healthcare professionals—including physicians, residents and fellows, NPs, and PAs—and pharmacists who are involved in the care of patients with GPP.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in accurate diagnosis, evidence-based treatment, and management of patients with GPP.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate recent evidence for new and emerging agents into treatment decisions for patients with GPP

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Boni Elewski, MD

James Elder Professor
Department Chair
Department of Dermatology
Heersink School of Medicine
The University of Alabama at Birmingham
Birmingham, Alabama

Boni Elewski, MD: consultant/advisor/speaker: Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo, Lilly, Novartis, UCB, Ortho dermatology; researcher (paid to institution): Abbvie, Anaptys-Bio, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Janssen, Leo, Lilly, Novartis, Ortho dermatology, Pfizer, UCB.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristine Kucera, PA-C, MPAS, DHS, as noted below:

Kristine Kucera, PA-C, MPAS, DHS: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol Myers Squibb, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sun Pharma, UCB.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 05, 2023, through October 04, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-249-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to NABP CPE Monitor Services within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 04, 2024. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

Successful completion of this CME activity, which included participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).